Dianthus Therapeutics, Inc.

NasdaqCM:DNTH Stock Report

Market Cap: US$705.3m

Dianthus Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Marino Garcia

Chief executive officer

US$496.0k

Total compensation

CEO salary percentage35.3%
CEO tenure3yrs
CEO ownershipn/a
Management average tenure1.2yrs
Board average tenure1.2yrs

Recent management updates

Recent updates

Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

Jul 03
Dianthus Therapeutics (NASDAQ:DNTH) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Marino Garcia's remuneration changed compared to Dianthus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$57m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$496kUS$175k

-US$44m

Compensation vs Market: Marino's total compensation ($USD496.02K) is below average for companies of similar size in the US market ($USD3.15M).

Compensation vs Earnings: Insufficient data to compare Marino's compensation with company performance.


CEO

Marino Garcia (58 yo)

3yrs

Tenure

US$496,022

Compensation

Mr. Marino Garcia, M.B.A., serves as President, CEO, Secretary and Director at Dianthus Therapeutics, Inc, whereas Director since September 2023. Mr. Garcia joined Dianthus in November of 2021. He served a...


Leadership Team

NamePositionTenureCompensationOwnership
Marino Garcia
President3yrsUS$496.02kno data
Ryan Savitz
CFO and Chief Business Officer & Treasurer1.2yrsUS$329.65k0%
$ 0
Simrat Randhawa
Chief Medical Officer2.5yrsUS$338.16k0.014%
$ 95.3k
Edward Carr
Chief Accounting Officer1.2yrsno datano data
Judson Taylor
Head of Technical Operationsno datano datano data
Jeffrey Stavenhagen
Chief Scientific Officerless than a yearno datano data
Jennifer Ruff
VP and Head of Investor Relations & Corporate Affairs.less than a yearno datano data
Adam Veness
Senior VP1.4yrsno datano data
Kristina Maximenko
Chief People Officerno datano datano data
Rashieda Gluck
Head of Clinical Development Operationsno datano datano data
Scott Nogi
Head of Business Operationsno datano datano data
Debra Segal
Head of Regulatory Affairsno datano datano data

1.2yrs

Average Tenure

54yo

Average Age

Experienced Management: DNTH's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Marino Garcia
President1.2yrsUS$496.02kno data
Leon Moulder
Independent Director1.2yrsUS$80.24k0%
$ 0
Alison Lawton
Independent Chairman of the Board3.9yrsUS$136.82k0%
$ 0
Jonathan Violin
Director5.3yrsUS$68.22k0%
$ 0
Steven Romano
Directorless than a yearno datano data
Paula Soteropoulos
Independent Director1.2yrsUS$92.83k0%
$ 0
Tomas Kiselak
Independent Director1.2yrsUS$71.26kno data

1.2yrs

Average Tenure

58yo

Average Age

Experienced Board: DNTH's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.